Effects of Symptom Management Education With Mobile Application in Gynecological Cancer Patients Receiving Chemotherapy
NCT ID: NCT06713122
Last Updated: 2024-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
70 participants
INTERVENTIONAL
2025-01-01
2026-02-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The spread of digitalisation has turned mobile learning into a kind of need or necessity rather than a preference. Increases the control of individuals over themselves and provides self-discipline.
The aim of this study was to evaluate the effect of symptom management training given with an artificial intelligence supported mobile application on supportive care needs, symptom severity and psychological well-being of gynaecological cancer patients receiving chemotherapy.
The study was planned as a randomised controlled trial. The population of the study will consist of patients who applied to Etlik City Hospital-Oncology Hospital-Day Outpatient Unit for the first time to receive chemotherapy treatment for gynaecological cancer and completed the first course.
The study will be conducted with a total of 70 patients, including 35 patients from the intervention group and 35 patients from the control group.
Research Hypotheses:
Gynaecological cancer patients receiving chemotherapyBetween the intervention group receiving symptom management training with a mobile application and the control group receiving standard care;
1. H1: There is a difference in terms of the severity of symptoms experienced.
2. H2: There is a difference in terms of supportive care needs.
3. H3: There is a difference in terms of psychological well-being levels. Data Collection Tools Descriptive Information Form, Edmonton Symptom Diagnostic Scale, Supportive Care Needs Scale, Psychological Well-Being Scale and Eastern Cooperative Oncology Group (ECOG) Performance Scale will be used as data collection tools.
Modules to be included in the Mobile Application:
The forms will be administered a total of three times, initially at the end of the 3rd and 5th cycle.
Module 1: Introducing Module Module 2: Application Usage Instruction Module Module 3: Recognise the Disease Module Module 4: Common Symptoms and Recommendations During Chemotherapy Treatment Module Module 5: Let's Fight Symptoms Together Module Module 6: Ask Anything - Counselling Module
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The spread of digitalisation has turned mobile learning into a kind of need or necessity rather than a preference. The use of web-based platforms in disease management leads to effective communication between the patient and the healthcare team. Thanks to the use of a web-based platform, communication between the patient and the caregiver increases, saving time and reducing costs. In addition to the benefits such as the ability of the health professional to plan the treatment planning by incorporating the patient's experiences, needs and concerns into the process and providing the benefit of access without spatial limitations, it also increases the control of individuals over themselves and provides self-discipline.
The aim of this study is to evaluate the effect of symptom management training given with an artificial intelligence supported mobile application developed for gynaecological cancer patients receiving chemotherapy on supportive care needs, symptom severity and psychological well-being.
The study was planned as a randomised controlled trial. Block randomisation will be used to assign patients to intervention and control groups.
The population of the study will consist of patients who applied to Etlik City Hospital-Oncology Hospital-Day Outpatient Unit for the first time to receive chemotherapy treatment for gynaecological cancer and completed the first course.
The sample of the study will consist of patients who applied to Etlik City Hospital-Oncology Hospital-Day Outpatient Unit to receive chemotherapy treatment for the first time and who meet the following inclusion criteria.
The study will be conducted with a total of 70 patients, including 35 patients from the intervention group and 35 patients from the control group (The sample number of the study was calculated by using the G Power programme using the data of a study in which mobile application intervention was carried out on cancer patients. Accordingly, the confidence interval was 95%; the margin of error was accepted as 5% and a total of 56 patients were found as 28 intervention and 28 control group. Considering that there may be losses during the mobile application intervention, the sample number was kept 25% higher than the calculated sample number.)
Research Hypotheses:
Gynaecological cancer patients receiving chemotherapyBetween the intervention group receiving symptom management training with a mobile application and the control group receiving standard care;
1. H1: There is a difference in terms of the severity of symptoms experienced.
2. H2: There is a difference in terms of supportive care needs.
3. H3: There is a difference in terms of psychological well-being levels. Data Collection Tools Descriptive Information Form, Edmonton Symptom Diagnostic Scale, Supportive Care Needs Scale, Psychological Well-Being Scale and Eastern Cooperative Oncology Group (ECOG) Performance Scale will be used as data collection tools.
* Data collection tools will be sent to patients via the application and will be asked to be filled in.
Modules to be included in the Mobile Application:
* The application will include module, registration, login and profile creation sections.
* The intervention group will be able to give feedback as they use the application.
* Motivational messages will be sent.
* At the end of the study, the mobile application will also be open to the control group.
* The forms will be administered a total of three times, initially at the end of the 3rd and 5th cycle.
* Module 1: Introducing Module
* Module 2: Application Usage Instruction Module
* Module 3: Recognise the Disease Module
* Module 4: Common Symptoms and Recommendations During Chemotherapy Treatment Module
* Module 5: Let's Fight Symptoms Together Module
* Module 6: Ask Anything - Counselling Module
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
İntervention Group- Group receiving Symptom Management Training with Mobile Application
Mobile application intervention will be applied to the intervention group. The evaluation tests will be repeated after the first cycle of chemotherapy treatment, at the 3rd and 5th cycles.
İntervention Group- Group receiving Symptom Management Training with Mobile Application
The application to be developed in the research will be both Android and IOS supported.
Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.
The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.
Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time.
Control Group
No intervention will be applied to the control group. The evaluation tests will be repeated after the first cycle of chemotherapy treatment, at the 3rd and 5th cycles.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
İntervention Group- Group receiving Symptom Management Training with Mobile Application
The application to be developed in the research will be both Android and IOS supported.
Monitoring the active use of the patients from the interface by the researcher and receiving individual and collective notifications in line with the profile that the patients receiving chemotherapy will create in the application will increase the usability of the application. Thus, the benefit that users receive after active use can be determined.
The content of the Let's fight the symptoms together module will be created by experts in the field and people will be able to actively use these methods while struggling with the symptoms they experience.
Patients may not always have the opportunity to reach a nurse or health professional. In symptom management with the mobile application, artificial intelligence will be trained by the researcher and integrated into the application will help patients reach the right information without wasting time.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years old
* Not previously diagnosed with cancer, diagnosed with gynaecological cancer for the first time and only
* Literate
* Who agreed to participate in the research
* No communication barrier
* Eastern Cooperative Oncology Group (ECOG) Performance Scale score below 3
* No diagnosed psychiatric illness
* Women who have an Android or IOS smartphone and can access the internet
Exclusion Criteria
* Chemotherapy treatment discontinued after the start of the study
* Not actively using the mobile application
* Not filling in the forms during the use of the Mobile Application
* The occurrence of another cancer during the research
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Esra Nur Erdoğan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esra Nur Erdoğan
Associate Investigator, PhD Student, Research Assistant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esra Nur Erdoğan, PhD Student
Role: STUDY_CHAIR
University of Health Sciences Gulhane Faculty of Nursing, Department of Obstetrics and Gynaecology
Gülten Güvenç, Prof.Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Health Sciences Gulhane Faculty of Nursing, Department of Obstetrics and Gynaecology
Tülay Eren, Asst. Prof.
Role: STUDY_CHAIR
Etlik City Hospital, Medical Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Etlik City Hospital-Oncology Hospital-Day Outpatient Unit
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Graetz I, Anderson JN, McKillop CN, Stepanski EJ, Paladino AJ, Tillmanns TD. Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial. Gynecol Oncol. 2018 Aug;150(2):311-317. doi: 10.1016/j.ygyno.2018.06.007. Epub 2018 Jun 11.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-442
Identifier Type: -
Identifier Source: org_study_id